Articles

Global Pharma Tech 2026: Key Insights and What to Expect

The Global Pharma Tech 2026 event in London promises to be a pivotal gathering for industry leaders. Attendees can expect insights on emerging technologies and investment opportunities.

Insights from the EuropaBio Biomanufacturing Policy Summit 2026

The EuropaBio Biomanufacturing Policy Summit 2026 brought together industry leaders to discuss the future of biomanufacturing. This article outlines key takeaways and implications for pharmaceutical teams.

Eli Lilly and Caitlin Clark: Transforming Indianapolis Sports Courts

Eli Lilly collaborates with Caitlin Clark to revitalize sports courts in Indianapolis, fostering community engagement and health. This initiative highlights the pharmaceutical giant's commitment to social responsibility.

NICE Approves Imfinzi for Stomach Cancer: Regulatory Update

NICE has backed the use of Imfinzi for perioperative treatment in stomach cancer, just 17 days after its UK approval. This article analyzes the regulatory update and its implications for the pharmaceutical landscape.

Global Pharma Tech 2026: Key Insights and Expectations

As the Global Pharma Tech event approaches, B2B readers can anticipate significant developments in the pharmaceutical technology landscape. This article outlines key takeaways and what to watch for during the event.

Doceree Launches Daily Command: A Game-Changer for Pharma Brand Teams

Doceree has unveiled Daily Command, an AI platform designed for pharma brand teams, co-built with industry leaders. This innovation promises to enhance marketing strategies and operational efficiency.

NICE Endorses Imfinzi for Stomach Cancer: Regulatory Insights

NICE has recently endorsed Imfinzi for perioperative use in stomach cancer, just 17 days post-UK approval. This article analyzes the regulatory updates and their implications.

Why Pharma Isn’t the First Voice in the Room: Insights and Implications

This article delves into the reasons behind pharma's delayed voice in critical discussions and its impact on the industry landscape.

The Case for Direct-to-Patient: Execution Challenges Ahead

This article discusses the clear case for direct-to-patient strategies in the pharmaceutical industry and the execution challenges that lie ahead.

Reframing Pharma Commercialization: New Possibilities

This article delves into innovative approaches in pharma commercialization, highlighting key insights and implications for industry stakeholders.

Join Our Pharmaceutical Network: Membership Opportunities

Discover the advantages of becoming a member of our pharmaceutical network. Learn how to contact us for membership and the value it brings to your business.

Roche's Elevidys Study Launch: Navigating EU Rejection

Roche is set to launch another study for Elevidys following the EMA's rejection. This article analyzes the implications for investors and pharma teams.

Veeva R&D and: Upcoming Event Preview

The Veeva R&D and event is set to take place in Copenhagen from June 15-17, 2026. This preview highlights key takeaways and companies to watch.

Orchard Therapeutics OTL-201: Innovation Passport for MPS-IIIA

Orchard Therapeutics has secured an Innovation Passport designation from the MHRA for its investigational gene therapy, OTL-201, targeting MPS-IIIA. This marks a significant step in accelerating development and access for patients with Sanfilippo syndrome type A.

NICE Technology Appraisals: Impact on Market Access for Novel Oncology Drugs

This article examines the role of NICE Technology Appraisals in shaping market access strategies for innovative oncology drugs, including Pembrolizumab.

MHRA Post-Brexit Drug Approval: What You Need to Know

Learn about the MHRA's new drug approval process post-Brexit and its impact on the availability of essential medications like Ozempic for diabetes.

CAR-T Cell Therapy Europe: Clinical Trials, Safety & Market Access Insights

Discover the latest insights on CAR-T Cell Therapy in Europe, focusing on clinical trials, safety profiles, and market access for hematologic cancers.

Biosimilar Uptake EU: Market Impact Post-Patent Expirations & HTA Regulation

This article examines how biosimilar adoption in the EU is reshaping the market landscape for biologics like Adalimumab after patent expirations and under HTA regulations.

Antibody-Drug Conjugates in Breast Cancer: Enhertu vs. Trodelvy in EU Market

This article compares Enhertu and Trodelvy, two leading antibody-drug conjugates, in their effectiveness for breast cancer treatment in the EU market.

EMA Conditional Marketing Authorization: Linvoseltamab for RRMM in EU

Linvoseltamab has received EMA's Conditional Marketing Authorization for treating relapsed/refractory multiple myeloma, offering new hope for patients in the EU.